| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011504888 |
| P356 | DOI | 10.2165/00002512-199404060-00006 |
| P698 | PubMed publication ID | 7521234 |
| P2093 | author name string | D McTavish | |
| A J Wagstaff | |||
| P2860 | cites work | Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs | Q28260986 |
| Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats | Q28324606 | ||
| The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms | Q28354362 | ||
| Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Diseasea | Q33296510 | ||
| A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease | Q33621285 | ||
| Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. | Q34578939 | ||
| Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease | Q34636158 | ||
| Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine | Q34648272 | ||
| Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease | Q34669866 | ||
| Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease | Q34731347 | ||
| Muscarinic Receptor Function and Acetylcholinesterase Activity after Chronic Administration of Tacrine to Mice at Therapeutic Drug Concentrations | Q48601207 | ||
| Tetrahydroaminoacridine improves passive avoidance retention defects induced by aging and medial septal lesion but not by fimbria-fornix lesion | Q48624682 | ||
| The effect of tacrine (THA) on cycloheximide- and basal forebrain lesion-induced memory deficit in rats | Q48628672 | ||
| Muscarinic subtype selectivity of tetrahydroaminoacridine: Possible relationship to its capricious efficacy | Q48638257 | ||
| Combination of atipamezole and tetrahydroaminoacridine/pilocarpine treatment suppresses high voltage spindle activity in aged rats | Q48673408 | ||
| Tetrahydroaminoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits | Q48707784 | ||
| Modulation of EEG rhythmicity and spike activity in the rat hippocampus by systemically administered tetrahydroaminoacridine, scopolamine and atipamezole | Q48722061 | ||
| The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing | Q48739991 | ||
| Negative Effects of Tacrine (Tetrahydroaminoacridine) and Methoxytacrine on the Metabolism of Acetylcholine in Brain Slices Incubated Under Conditions Stimulating Neurotransmitter Release | Q48764100 | ||
| Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain | Q48895769 | ||
| Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA). | Q48896672 | ||
| Effects of tetrahydro-9-aminoacridine on cortical and hippocampal neurons in the rat: an in vivo and in vitro study | Q48897660 | ||
| Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats | Q48957090 | ||
| Studies on new, centrally active and reversible acetylcholinesterase inhibitors | Q48959304 | ||
| Modulation of gamma-aminobutyric acid release in cerebral cortex by fluoride, phorbol ester, and phosphodiesterase inhibitors: differential sensitivity of acetylcholine release to fluoride and K+ channel blockers | Q49050274 | ||
| A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group | Q52026922 | ||
| Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study | Q52057810 | ||
| The effects of tacrine and zacopride on the performance of adult rats in the working memory task | Q52062457 | ||
| Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease | Q52067652 | ||
| Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. | Q52087212 | ||
| Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats | Q52104144 | ||
| Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models | Q52104748 | ||
| Multiple effects of tetrahydroaminoacridine on the cholinergic system: biochemical and behavioural aspects | Q52111280 | ||
| Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported | Q52112673 | ||
| Effects of cholinergic drugs on learning impairment in ventral globus pallidus-lesioned rats | Q52116897 | ||
| Tetrahydroaminoacridine selectively attenuates NMDA receptor-mediated neurotoxicity | Q69925852 | ||
| Tetrahydroaminoacridine inhibits high voltage spindle activity in aged rats after acute and chronic treatment | Q70147939 | ||
| Blockade of voltage-dependent 42K efflux from rat brain synaptosome by minaprine and tetrahydroaminoacridine | Q70180833 | ||
| Physostigmine inhibition of 3',5'-cyclic AMP phosphodiesterase from cat sciatic nerve | Q70198103 | ||
| The effect of tacrine on acetylcholine overflow in the heart | Q70244912 | ||
| Interaction of tacrine at M1 and M2 cholinoceptors in guinea pig brain | Q72590069 | ||
| An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes | Q72870562 | ||
| Tacrine in Alzheimer's disease | Q93879915 | ||
| Effect of acute arecoline, tacrine, and arecoline + tacrine post-training administration on retention in late middle-aged mice | Q52125106 | ||
| Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment | Q52222101 | ||
| Chronic treatments with cholinoceptor drugs influence spatial learning in rats | Q52228711 | ||
| Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats | Q52240599 | ||
| Learning deficits in aged rats pretreated chronically with barbital and tested late in abstinence: alleviation by tetrahydroaminoacridine | Q52243706 | ||
| Tetrahydroaminoacridine facilitates passive avoidance learning in rats with nucleus basalis magnocellularis lesions | Q52244318 | ||
| Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type | Q52259713 | ||
| Effects of nicotine on local cerebral glucose utilization in the rat. | Q52267234 | ||
| Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain | Q52454833 | ||
| In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers | Q53030770 | ||
| Tacrine for treating Alzheimer's disease | Q53179456 | ||
| Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects | Q53180360 | ||
| Somatostatin and cognitive functions in Alzheimer's disease--the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine | Q53181237 | ||
| Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease | Q53182756 | ||
| Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. | Q53186098 | ||
| Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study | Q53186322 | ||
| Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes | Q53188763 | ||
| Hepatotoxicity of tetrahydroaminoacridine | Q53190129 | ||
| THA and Alzheimer's disease | Q53193177 | ||
| Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease | Q53196303 | ||
| Long-term use of tacrine | Q53204306 | ||
| An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease | Q53207687 | ||
| Mechanisms of the tetrahydroaminoacridine effect on action potential and ion currents in myelinated axons | Q53296694 | ||
| Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers | Q53297359 | ||
| Inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on the potassium current of rabbit sinoatrial node | Q53299131 | ||
| Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease | Q53317324 | ||
| Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola. | Q54398592 | ||
| Tacrine in Alzheimer's disease | Q56763713 | ||
| Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice | Q57136373 | ||
| The Prevalence of Dementia in Europe: A Collaborative Study of 1980–1990 Findings | Q57782178 | ||
| Block of the cardiac pacemaker current (If) in the rabbit sino-atrial node and in canine Purkinje fibres by 9-amino-1,2,3,4-tetrahydroacridine | Q61910336 | ||
| Effects of tacrine, aminopyridines, and physostigmine on acetylcholinesterase, acetylcholine release, and potassium currents | Q62900132 | ||
| THA increases action potential duration of central histamine neurons in vitro | Q67242674 | ||
| Effects of tacrine on insulin secretion and 86Rb+ and 45Ca++ efflux from rat pancreatic islets | Q67865042 | ||
| Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro | Q67960354 | ||
| Prevention by choline of the depletion of membrane phosphatidylcholine by a cholinesterase inhibitor | Q68251729 | ||
| Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis | Q68648020 | ||
| Tacrine and lecithin in Alzheimer's disease | Q68780451 | ||
| Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type | Q69033453 | ||
| Effects of THA on ionic currents in myelinated axons of Xenopus laevis | Q69094425 | ||
| Tetrahydroaminoacridine but not 4-aminopyridine inhibits high-affinity choline uptake in striatal and hippocampal synaptosomes | Q69339864 | ||
| Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose | Q69398829 | ||
| Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? | Q69449361 | ||
| Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients | Q69597522 | ||
| Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine | Q69681544 | ||
| Tacrine slows the rate of ageing of sarin-inhibited acetylcholinesterase | Q69683824 | ||
| The effect of an acute nicotine infusion on the local cerebral glucose utilization of the awake rat | Q69745115 | ||
| Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine | Q35168053 | ||
| Putative mechanisms of action of tacrine in Alzheimer's disease. | Q35342313 | ||
| Neuroreceptor changes in Alzheimer disease | Q35659804 | ||
| 9-Amino-1,2,3,4-tetrahydroacridine (THA) is a potent blocker of cardiac potassium channels | Q35755032 | ||
| Tetrahydroaminoacridine (tacrine) stimulates neurosecretion at mammalian motor endplates | Q35888481 | ||
| Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease | Q36067600 | ||
| Tacrine: A pharmacological review | Q36673752 | ||
| Long-term treatment with tacrine (THA) in Alzheimer's disease--evaluation of neuropsychological data | Q36744692 | ||
| Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial | Q36884943 | ||
| Diagnostic and pharmacological approaches in Alzheimer's disease | Q36972797 | ||
| Tacrine in relation to amino acid transmitters in Alzheimer's disease. | Q37578195 | ||
| Alternatives in the treatment of memory loss in patients with Alzheimer's disease | Q37775182 | ||
| Shifting patterns of cortical cholinesterases in Alzheimer's disease: implications for treatment, diagnosis, and pathogenesis. | Q38137707 | ||
| A psychopharmacological perspective of cognitive functions. II. Specific pharmacologic agents | Q38161282 | ||
| Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence | Q38365810 | ||
| Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: a pilot study | Q38719669 | ||
| Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease | Q38723971 | ||
| Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies | Q39125647 | ||
| Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients | Q39510569 | ||
| Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation | Q40145746 | ||
| Clinical studies in Alzheimer patients with positron emission tomography | Q40621341 | ||
| Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. | Q41099297 | ||
| Histamine-induced arousal in the conscious and pentobarbital-pretreated rat. | Q41621997 | ||
| Open trial of tacrine therapy in 70 HIV-infected patients. | Q41893410 | ||
| Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro | Q41963937 | ||
| Effects of velnacrine, tacrine and physostigmine on tetanic twitch responses at the rat neuromuscular junction | Q42099013 | ||
| Inhibitory effect of 1,2,3,4-tetrahydro-9-aminoacridine on the depolarization-induced release of GABA from cerebral cortex | Q42144280 | ||
| Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes | Q42193084 | ||
| Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase | Q42193896 | ||
| Comparison of 4-aminopyridine and tetrahydroaminoacridine on basal forebrain neurons | Q42482741 | ||
| Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats | Q42484825 | ||
| Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease | Q42603612 | ||
| Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses | Q42713800 | ||
| The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro | Q42847596 | ||
| The cholinergic system and the excitatory amino acids in Alzheimer's disease | Q43537493 | ||
| Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices | Q43543591 | ||
| Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine | Q43782041 | ||
| Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients | Q43852948 | ||
| Investigation of the mechanism of the effect of tacrine (tetrahydroaminoacridine) on the metabolism of acetylcholine and choline in brain cortical prisms | Q43888912 | ||
| Tetrahydroaminoacridine block of N-methyl-D-aspartate-activated cation channels in cultured hippocampal neurons | Q43957035 | ||
| Structure-activity investigation of the alteration of the physical state of the skeletal network of proteins in human erythrocyte membranes induced by 9-amino-1,2,3,4-tetrahydroacridine | Q44077660 | ||
| Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human serum and urine with those of in vitro metabolic products from hepatic microsomes | Q44091007 | ||
| A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group | Q44110810 | ||
| Influence of tetrahydro-9-aminoacridine on excitatory amino acid release | Q44130586 | ||
| Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease | Q44223667 | ||
| Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats | Q44324648 | ||
| Tetrahydroaminoacridine, 3,4 diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates | Q44458753 | ||
| Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography | Q44486170 | ||
| Reversibility of the inhibition of acetylcholinesterase by tacrine | Q44714988 | ||
| 9-Amino-1,2,3,4-tetrahydroacridine is a potent inhibitor of histamine N-methyltransferase | Q44760156 | ||
| Tacrine in Alzheimer's disease | Q44777869 | ||
| Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine | Q45017014 | ||
| Positive and negative effects of tacrine (tetrahydroaminoacridine) and methoxytacrine on the metabolism of acetylcholine in brain cortical prisms incubated under "resting" conditions | Q45055455 | ||
| Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock | Q45130083 | ||
| Memory facilitation by histamine | Q45207574 | ||
| Tetrahydroaminoacridine and physostigmine have opposing effects on probability of transmitter release at the frog neuromuscular junction | Q45262334 | ||
| Characterisation of dopamine and serotonin uptake inhibitory effects of tetrahydroaminoacridine in rat brain | Q45272933 | ||
| 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones | Q45385687 | ||
| Effects of atipamezole and tetrahydroaminoacridine on nucleus basalis lesion-induced EEG changes. | Q45999072 | ||
| Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us? | Q46543100 | ||
| Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report | Q46605078 | ||
| Tetrahydroaminoacridine increases acetylcholine synthesis and glucose oxidation by mouse brain slices in vitro | Q46616845 | ||
| SPECT brain imaging in Alzheimer's disease during treatment with oral tetrahydroaminoacridine and lecithin | Q46622236 | ||
| Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors | Q46659151 | ||
| Therapeutic trials using tacrine and other cholinesterase inhibitors | Q46914279 | ||
| Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. | Q48119553 | ||
| Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease | Q48161693 | ||
| Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles | Q48176447 | ||
| Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons | Q48195378 | ||
| 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current | Q48208220 | ||
| Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease | Q48222617 | ||
| Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains | Q48265799 | ||
| Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats | Q48267913 | ||
| Positron emission tomography study of [11C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain | Q48284078 | ||
| THA does not affect sleep or EEG spectral power in Alzheimer's disease | Q48284449 | ||
| Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the beta-adrenoceptor transduction system | Q48319946 | ||
| Selective loss of central cholinergic neurons in Alzheimer's disease | Q48342983 | ||
| Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling | Q48360983 | ||
| Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients | Q48372876 | ||
| Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. | Q48372886 | ||
| Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. | Q48384635 | ||
| The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease | Q48391011 | ||
| A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group | Q48418557 | ||
| Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain | Q48436093 | ||
| Comparative effects of alpha-2 receptor agents and THA on the performance of adult and aged rats in the delayed non-matching to position task | Q48549306 | ||
| P433 | issue | 6 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| pharmacokinetics | Q323936 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 510-540 | |
| P577 | publication date | 1994-06-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease | |
| P478 | volume | 4 |
| Q44193387 | A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. |
| Q43671271 | Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking |
| Q43778493 | Action of tacrine on muscarinic receptors in rat intestinal smooth muscle. |
| Q56983873 | Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine |
| Q92327129 | Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement |
| Q42116604 | An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function |
| Q34342293 | Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders |
| Q35802571 | Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease |
| Q42541283 | Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release |
| Q40503541 | Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy |
| Q34677583 | Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention |
| Q33637687 | Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease |
| Q40472033 | Clinical Pharmacokinetics of Tacrine |
| Q40943329 | Cognition enhancers in age-related cognitive decline |
| Q74457403 | Comparative Biomembrane Permeation of Tacrine Using Yucatan Minipigs and Domestic Pigs as the Animal Model |
| Q52115210 | Controlled transdermal iontophoresis by ion-exchange fiber |
| Q38981991 | Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches |
| Q40594550 | Differential diagnosis of dementia, delirium and depression. Implications for drug therapy |
| Q42719441 | Donepezil. |
| Q33761849 | Donepezil. Pharmacoeconomic implications of therapy |
| Q33914241 | Donepezil: a review of its use in Alzheimer's disease |
| Q46965271 | Dose-related effects of the acetylcholinesterase inhibitor tacrine on cocaine and food self-administration in rats. |
| Q42460714 | Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats |
| Q41078386 | Effect of tacrine on intracellular calcium in cholinergic SN56 neuronal cells |
| Q35733058 | Enduring effects of tacrine on cocaine-reinforced behavior: Analysis by conditioned-place preference, temporal separation from drug reward, and reinstatement |
| Q41119615 | Galanthamine |
| Q51548277 | Galanthamine in Alzheimer's disease : a new alternative to tacrine? |
| Q35079851 | Hypolipidemic and weight reducing activity of the ethanolic extract of Tamarindus indica fruit pulp in cafeteria diet- and sulpiride-induced obese rats |
| Q40644109 | Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders |
| Q31105481 | Identification of selective inhibitors of acetylcholinesterase from a combinatorial library of 2,5-piperazinediones |
| Q34732916 | Inhibition of tacrine oral clearance by cimetidine |
| Q53223082 | Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? |
| Q48548934 | Kinetics of Muscarinic Reduction of I sAHP in Hippocampal Neurons: Effects of Acetylcholinesterase Inhibitors |
| Q52000682 | Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia : Results of a Multicentre, Double-Blind, Placebo-Controlled Study |
| Q35891535 | Long-term cholinesterase inhibitor treatment of Alzheimer's disease. |
| Q43151006 | Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. |
| Q53325576 | Non-insulin-dependent diabetes mellitus and Alzheimer's disease |
| Q77676004 | Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat |
| Q40574243 | Psychotropic drugs, aging and community care |
| Q33638239 | Realistic expectations for the management of Alzheimer's disease |
| Q40931095 | Recent advances in geriatric psychopharmacology |
| Q48597495 | Repeated administration of tacrine to normal rats: Effects on cholinergic, glutamatergic, and GABAergic receptor subtypes in rat brain using receptor autoradiography |
| Q51980431 | Response surface methodology to investigate the iontophoretic delivery of tacrine hydrochloride |
| Q43631515 | Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors |
| Q40861679 | Tacrine interacts with different sites on nicotinic receptor subtypes in SH-SY5Y neuroblastoma and M10 cells |
| Q38558148 | The genetics of dementia in late life |
| Q47724056 | Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease |
| Q33660855 | Tranquilizers, stimulants, and enhancers of cognition. |
| Q37253034 | Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects |
| Q74312513 | Transdermal iontophoresis of tacrine in vivo |
| Q36528732 | Transdermal treatment options for neurological disorders: impact on the elderly |
| Q52058562 | Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential |
Search more.